Navigation Links
Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
Date:1/10/2008

substantial risks and uncertainties. You can identify these statements by the fact that they use words such as "will", "anticipate", "estimate", "expect", "project", "forecast", "intend", "plan", "believe" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or events. Among the factors that could cause actual results to differ materially from those described or projected herein are the following: risks relating to the Company's ability to maintain its Nasdaq listing (including the risk that the Company may not successfully appeal a Nasdaq delisting determination); Amarin's ability to maintain sufficient cash and other liquid resources to meet its operating and debt service requirements; the success of Amarin's research and development activities, including its planned clinical trials in cardiovascular disease and; decisions by regulatory authorities regarding whether and when to approve Amarin's drug applications, as well as their decisions regarding labeling and other matters that could affect the commercial potential of Amarin's products; the speed with which regulatory authorizations, pricing approvals and product launches may be achieved; the success with which developed products may be commercialized; competitive developments affecting Amarin's products under development; the effect of possible domestic and foreign legislation or regulatory action affecting, among other things, pharmaceutical pricing and reimbursement, including under Medicaid and Medicare in the United States, and involuntary approval of prescription medicines for over-the-counter use; Amarin's ability to protect its patents and other intellectual property; claims and concerns that may arise regarding the safety or efficacy of Amarin's product candidates; governmental laws and regulations affecting Amarin's operations, including those affecting taxation; general changes in International and US generally accepted accountin
'/>"/>
SOURCE Amarin Corporation Plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
2. Amarin to Present at 4th Annual Bio Investor Forum
3. Amarin Announces Initiation of Cardiovascular Development Strategy
4. Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference
5. Amarin Signs Agreement to Acquire Ester Neurosciences
6. NPS Pharmaceuticals Commences Tender Offer for 3.0% Convertible Notes Due 2008
7. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Research and Markets  has announced the addition of the ... report to their offering. This report analyzes the ... by the following Product Segments: Media, Sera, and Reagents. ... Canada , Japan , Europe ... America . Annual estimates and forecasts are provided for the ...
(Date:8/19/2014)... XenoTech announces an exclusive partnership with ... from bioactive small molecules. Based on an ... convenient and timely assessment of critical metabolite and ... of Commercial Operations, Christian Darabant, “the value of ... be measured directly by comparison with the approximate ...
(Date:8/19/2014)... Aug. 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" ... reported results of its Oral Amphotericin B (Oral ... The study, conducted by ImmuneCarta®, the immune monitoring ... effectiveness of Oral Amp B in reactivating ... individuals despite intensive treatment with antiretroviral therapy. ...
(Date:8/18/2014)... , Aug. 18, 2014 ... of advanced consumer medical devices said that ... was interviewed by CEOLIVE.TV as part of ... entire interview is available at http://ceolive.tv/bioelectronics-corp-otc-biel/biel-videos/2282-ceolive-tv-interview-bioelectronics-corp-otcqb-biel ... Kotak explains to investors the unique advantages ...
Breaking Biology Technology:Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3
... 16 NanoSmart™ Pharmaceuticals, Inc., a California corporation developing ... received a Notice of Allowance for a US patent ... "We have taken an approach to targeting tumors that ... CEO of the company. "While most of cancer research ...
... Announces Record Second Quarter 2010 Results -- HARBIN, China, Aug. 16 /PRNewswire-Asia/ -- ... ... --> ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first ...
... Aug. 16 NeoStem, Inc. (NYSE Amex: ... company with product and service revenues, global research and ... U.S. adult stem cells, China adult stem cells, and ... quarter 2010. Second Quarter Results ...
Cached Biology Technology:NanoSmart™ Pharmaceuticals, Inc. Receives Patent Allowance for Tumor Targeting Platform Technology 2Nutrastar International Inc. Announces Record Second Quarter 2010 Results 2Nutrastar International Inc. Announces Record Second Quarter 2010 Results 3Nutrastar International Inc. Announces Record Second Quarter 2010 Results 4Nutrastar International Inc. Announces Record Second Quarter 2010 Results 5Nutrastar International Inc. Announces Record Second Quarter 2010 Results 6Nutrastar International Inc. Announces Record Second Quarter 2010 Results 7Nutrastar International Inc. Announces Record Second Quarter 2010 Results 8Nutrastar International Inc. Announces Record Second Quarter 2010 Results 9Nutrastar International Inc. Announces Record Second Quarter 2010 Results 10NeoStem Provides Second Quarter Update 2NeoStem Provides Second Quarter Update 3NeoStem Provides Second Quarter Update 4
(Date:8/20/2014)... In leaves, photosystem 1 (PS1) absorbs light and ... of carbon dioxide to biomass. Photovoltaic devices, mostly ... light but produce electricity. One approach for the ... replacing the semi-conductor with the isolated membrane protein ... isolates a highly stable PS1 from thermophilic cyanobacteria ...
(Date:8/20/2014)... Aug. 20, 2014  The second annual Biometrics ... Tampa, Florida on September ... Steven Rahman, Director, Technology and Strategy at Samsung, and ... The theme of this year,s event is Mobility ... "Biometrics UnPlugged: Mobility at the Crossroads ...
(Date:8/19/2014)... students, chances of completing introductory biology courses and ... implemented a comprehensive student success program, employing various ... , Through a grant from the Texas Higher ... and Biochemistry embarked on a pilot program focusing ... and "Introductory Biology" for science majors. These two ...
Breaking Biology News(10 mins):A semi-artificial leaf faster than 'natural' photosynthesis 2Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3
... The Press Room will be on the fifth floor of ... the Main Lecture Room, offering free wireless access, the book ... January 6 through Friday, January 8, 7:30 a.m.-5:00 p.m., and ... press is free. Two events are open to the ...
... glioma, the most common primary brain tumor, new findings ... cancer. A UCSF-led team of scientists has identified ... stem cells underly a type of glioma called oligodendroglioma. ... to therapy than other brain tumors such as glioblastoma ...
... the allergic reactions that asthmatics suffer towards a common ... had the mould growing in their own lungs. ... Glenfield Hospital has been published in the December 2010 ... Critical Care Medicine . The team based in ...
Cached Biology News:Joint Mathematics Meetings in New Orleans Jan. 6-9 2Joint Mathematics Meetings in New Orleans Jan. 6-9 3Joint Mathematics Meetings in New Orleans Jan. 6-9 4Joint Mathematics Meetings in New Orleans Jan. 6-9 5Joint Mathematics Meetings in New Orleans Jan. 6-9 6Joint Mathematics Meetings in New Orleans Jan. 6-9 7Cell of origin for brain tumors may predict response to therapy 2Cell of origin for brain tumors may predict response to therapy 3New asthma research breaks the mold 2
... The ULS cDNA Synthesis and Labeling Kit ... hybridization experiments. First unmodified cDNA is made ... cDNA using an Oligo(dT) primer. Unlike other ... used in the reverse transcription reaction. This ...
... Dot Blot Kits overcome this limitation and ... a wide range in low-density protein array ... They are ideal for performing reverse-phase protein ... for the presence of low abundant antigens. ...
AC input: 50-60 Hz230 V...
... arraying proteins of interest with sensitive ... DiscoverLight Protein Array Kits allow for ... lysate or antibody in a low-density ... designed nitrocellulose membranes with a 384-grid ...
Biology Products: